Molecule Details
| InChIKey | CXGTZJYQWSUFET-IBGZPJMESA-N |
|---|---|
| Compound Name | Tesaglitazar |
| Canonical SMILES | CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 6.55 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB06536 |
|---|---|
| Drug Name | Tesaglitazar |
| CAS Number | 251565-85-2 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 20... |
Categories: Acids, Carbocyclic Alkanes Alkanesulfonic Acids Hydrocarbons, Acyclic Sulfonic Acids Sulfur Acids Sulfur Compounds
Cross-references: BindingDB: 28798 CHEMBL282686 ChemSpider: 180999 PDB: AZ2 PubChem:208901 Wikipedia: Tesaglitazar ZINC: ZINC000001550769